Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.39 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.39 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.39 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12589813 | 1.00 | KMT2A (0.44) | KMT2AACEMEN1ALDH1A1CTSS | |
| SCHEMBL3196097 | 0.89 | ALDH1A1 (0.41) | KMT2AMEN1ALDH1A1CTSSCYP1A2 | |
| SCHEMBL700092 | 0.87 | NR1H2 (0.44) | KMT2AACECTSSHTRA1CYP1A2 | |
| SCHEMBL6847765 | 0.87 | NR1H2 (0.44) | KMT2AACECTSSHTRA1CYP1A2 | |
| SCHEMBL6847598 | 0.87 | NR1H2 (0.44) | KMT2AACECTSSHTRA1CYP1A2 | |
| SCHEMBL7374046 | 0.87 | ACE (0.41) | KMT2AACEMEN1CTSSHTRA1 | |
| SCHEMBL6847724 | 0.86 | ACE (0.54) | KMT2AACECTSSHTRA1CYP1A2 | |
| SCHEMBL9542869 | 0.86 | ACE (0.54) | KMT2AACECTSSHTRA1CYP1A2 | |
| SCHEMBL12646680 | 0.86 | ACE (0.54) | KMT2AACECTSSHTRA1CYP1A2 | |
| SCHEMBL7380297 | 0.86 | ACE (0.54) | KMT2AACECTSSHTRA1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968733-B2 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2011-06-28 | — | — | US | disclosed |
| US-7659305-B2 | 4-carbo- or heterocyclic alkyl-, oxy-, amino-, and thio-substituted; e.g., 2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid; controlling neurotransmitter release; uses include general treatment of pain, particularly neuropathic pain. | PFIZER INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659305-B2 | 4-carbo- or heterocyclic alkyl-, oxy-, amino-, and thio-substituted; e.g., 2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid; controlling neurotransmitter release; uses include general treatment of pain, particularly neuropathic pain. | PFIZER INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-7659305-B2 | 4-carbo- or heterocyclic alkyl-, oxy-, amino-, and thio-substituted; e.g., 2S, 4S)-4-(3-Chloro-phenoxy)-pyrrolidine-2-carboxylic acid; controlling neurotransmitter release; uses include general treatment of pain, particularly neuropathic pain. | PFIZER INC. (US) | 2010-02-09 | — | — | US | disclosed |
| US-20090306407-A1 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | GIFU UNIVERSITY (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-2058301-A1 | PYRROLIDINE ANALOGUE FOR PREVENTING NEUROGENIC PAIN AND METHOD FOR PRODUCTION THEREOF | Gifu University (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306407-A1 | Pyrrolidine analogue for preventing neurogenic pain and method for production thereof | HNMT, OPRK1, OPRL1 | KMT2A 3653/4885ACE 727/4885MEN1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.